Disease flare after gefitinib discontinuation

Respiratory Investigation
Hiroaki AkamatsuToshiaki Takahashi

Abstract

A recent retrospective analysis found that 23% of non-small cell lung cancer patients who acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) demonstrated "disease flare" after discontinuation of EGFR-TKIs. However, limitations of this study present the need for further investigation to elucidate this phenomenon in more detail. We reviewed the clinical records of EGFR mutated patients with advanced lung adenocarcinoma who were treated with gefitinib monotherapy in our hospital between January 2007 and December 2010. Disease flare was defined as unexpected interventions (e.g. radiation therapy or pleural drainage), hospitalization, or death attributable to disease progression after gefitinib discontinuation. Among 52 eligible patients, only two experienced disease flare (4%; 95% confidence interval: 1-13%). In both cases, interval time from gefitinib discontinuation to disease flare was 11 days, and the brain was the site of flare. Survival time after gefitinib was significantly shorter in the flare patients (78 and 97 days, respectively) compared with the no-flare patients (median 388 days). Our analysis demonstrated a lower incidence rate of disease flare after gefitinib discontinua...Continue Reading

References

Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory J RielyVincent A Miller
Aug 21, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tatsuya KatayamaTetsuya Mitsudomi
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Aug 23, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jamie E ChaftGregory J Riely
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Dec 5, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Naruo YoshimuraShinzoh Kudoh
Jun 28, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Eunyoung LeeDae Seog Heo
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Jan 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardPasi A Jänne

❮ Previous
Next ❯

Citations

May 5, 2016·World Journal of Surgical Oncology·Pimpin IncharoenArtit Jinawath
Jun 21, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kei KunimasaYoshikazu Kotani
Oct 6, 2017·Journal of Oncology Practice·Thomas J SmithGregory Masters

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinica Chimica Acta; International Journal of Clinical Chemistry
Shuai WangYuankai Shi
Zhonghua zhong liu za zhi [Chinese journal of oncology]
Lu YangMeina Wu
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Shigeki UmemuraMitsune Tanimoto
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Qing ZhouYi-Long Wu
© 2022 Meta ULC. All rights reserved